Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21307204 | 1.00 | RIPK1 (0.71) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL17321336 | 1.00 | RIPK1 (0.71) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL17312866 | 0.93 | RIPK1 (0.62) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL17312867 | 0.93 | RIPK1 (0.62) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL21678864 | 0.89 | RIPK1 (0.60) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL21678865 | 0.89 | RIPK1 (0.60) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL17312437 | 0.87 | RIPK1 (0.55) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL17312442 | 0.87 | RIPK1 (0.55) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL19037414 | 0.84 | RIPK1 (0.51) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL17312780 | 0.83 | RIPK1 (0.51) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885NR1I2 1725/4885CYP2C9 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.